Aratana's Drug Pipeline Suggests Revenue Growth Could Continue For Years
September 06, 2016 at 13:33 PM EDT
Bruce Jackson of Lake Street assumes coverage of Aratana Therapeutics Inc (NASDAQ: PETX) with a Buy rating and $15 target price, saying ...